Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome  by Nishihori, Taiga et al.
Biol Blood Marrow Transplant 20 (2014) 776e780American Society for Blood
ASBMT
and Marrow TransplantationPretransplantation 5-Azacitidine in High-Risk
Myelodysplastic Syndrome
Taiga Nishihori 1, Janelle Perkins 1, Asmita Mishra 1,
Rami Komrokji 2, Jongphil Kim 3,
Mohamed A. Kharfan-Dabaja 1, Lia Perez 1, Jeffrey Lancet 2,
Hugo Fernandez 1, Alan List 2, Claudio Anasetti 1,
Teresa Field 1,*
1Department of Blood and Marrow Transplantation, H. Lee Mofﬁtt Cancer Center and Research
Institute, Tampa, Florida
2Department of Malignant Hematology, H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa,
Florida
3Biostatistics Core, H. Lee Mofﬁtt Cancer Center and Research Institute, Tampa, FloridaArticle history:
Received 27 December 2013
Accepted 11 February 2014
Key Words:
5-Azacitidine
MDS
Hypomethylating agent
Allogeneic hematopoietic cell
transplantationFinancial disclosure: See Acknowl
* Correspondence and reprint re
ment of Blood and Marrow Transp
and Research Institute, 12092 Mag
E-mail address: teresa.ﬁeld@mo
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
We prospectively evaluated the allogeneic hematopoietic cell transplantation (HCT) outcomes in high-risk
myelodysplastic syndrome (MDS) patients who received pretransplantation 5-azacitidine. Twenty-ﬁve pa-
tients evaluated for allogeneic HCT consult and considered medically eligible for a donor search were
enrolled. Azacitidine was administered at 75 mg/m2 for 5 to 7 days every 4 weeks until a suitable donor was
found. A median of 3 (range, 0 to 6) cycles of 5-azacitidine were administered. Preallogeneic HCT responses to
5-azacitidine, based on the International Working Group criteria, were 48% partial response, 33% stable
disease, and 19% progressive disease. Four patients did not proceed to allogeneic HCT. Twenty-one patients, a
median age of 55 (range, 25 to 67) years, received allogeneic HCT after myeloablative pharmacokinetically
targeted i.v. busulfan and ﬂudarabine conditioning regimen. Donors were either HLA-matched related or
unrelated, except for 1 mismatch unrelated donor. With a median follow-up of 30 months, 1-year relapse-free
and overall survivals were 52% (95% conﬁdence interval [CI], 30% to 71%) and 62% (95% CI, 38% to 79%),
respectively. Preallogeneic HCT 5-azacitidine administration was well tolerated and provided reasonable
disease control before allogeneic HCT. (Registered at ClinicalTrials.gov as NCT00660400).
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Myelodysplastic syndrome (MDS) is composed of groups
of clonal bone marrow disorders characterized by peripheral
blood cytopenias due to ineffective hematopoiesis and by a
risk of progression to acutemyelogenous leukemia (AML) [1].
The availability of hypomethylating agents, including 5-
azacitidine and decitabine, has changed the landscape of
MDS treatment. Azacitidine results in hematologic improve-
ments in approximately 25% to 50% of cases and complete
response (CR) in 10% to20%with improved survival compared
to supportive care alone in high-risk MDS [2,3]. Although
hypomethylating agents can induce hematological and cyto-
genetic responses, these therapies do not appear to eradicate
MDS clones. Allogeneic hematopoietic cell transplantation
(HCT) is the only known curative therapy for MDS and is
offered to selectedpatientswhoare considered tohavehigher
risk of AML progression and who are ﬁt for the procedure [4].
The use of hypomethylating agents as a bridge to more
deﬁnitive therapy is increasing based on the premise that
inhibition of DNA methyltransferases results in hypo-
methylation and, consequently, might result in reactivation
of tumor suppressor genes, terminal differentiation, and
apoptosis of neoplastic cells with reduction of tumor burdenedgments on page 780.
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[6-9], though very few were conducted prospectively [10].
We hypothesized that the administration of 5-azaciditine
before the conditioning regimen may reduce the risk of MDS
relapse after allogeneic HCT. In addition to its direct anti-
tumor effect, 5-azaciditine may potentiate the effect of high-
dose chemotherapy or promote the expression of targets
critical to the effect of graft-versus-tumor response. There-
fore, we designed a pilot prospective trial to evaluate the role
of pretransplantation 5-azaciditine therapy in high-risk MDS
patients on the outcomes after allogeneic HCT.METHODS
Patient Population
Eligible patients were 18 to 68 years of age, had histologically conﬁrmed
high-risk MDS, deﬁned by International Prognostic Scoring System [11] >1,
AML deriving from backgroundMDS, or therapy-related MDS. Patients must
have had a serum bilirubin level 1.5 times the upper limit of normal (ULN)
(higher levels were acceptable if attributed to active hemolysis or ineffective
erythropoiesis), aspartate aminotransferase or alanine aminotransferase 2
times the ULN, serum creatinine 1.5 times the ULN, and Karnofsky per-
formance status 70%. Patients were excluded if they had known or sus-
pected hypersensitivity to 5-azacitidine or mannitol; were pregnant or
lactating; or had active central nervous system malignancy, active infection,
or a history of solid organ malignancy, with the exception of nonmelanoma
skin cancers.
The study was approved by the Institutional Review Board of the Uni-
versity of South Florida. All study participants provided voluntary written
informed consent. This clinical trial was conducted in accordance with the
Declaration of Helsinki and the International Conference of Harmonization
for Good Clinical Practice. The trial was registered at www.clinicaltrials.gov
as NCT00660400.Transplantation.
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The primary objective of the study was to evaluate relapse-free survival
(RFS) 1 year after allogeneic HCT in MDS patients receiving at least 1 com-
plete cycle of 5-azacitidine in the pretransplantation setting. Secondary
objectives included assessment of response to 5-azacitidine, proportion of
patients enrolled who subsequently proceeded to allogeneic HCT, and
overall survival (OS) 1 year from the ﬁrst dose of 5-azacitidine, time to
progression of MDS, and time to progression to AML.
Patients with high-risk MDS evaluated in blood and marrow trans-
plantation clinic who were potentially eligible for allogeneic HCT were
considered for trial enrollment. After informed consent was documented
and the donor search was initiated, 5-azacitidine was administered per
standard practice. The recommended dose of 5-azacitidine was 75 mg/m2/
day intravenously or subcutaneously, daily for 5 to 7 days, every 4 weeks.
After administration of the recommended dosage for the ﬁrst cycle, dosage
adjustments for the subsequent cycles were allowed based on the suggested
dosing guidelines [12]. The number of cycles of 5-azacitidine treatment was
not speciﬁed in the protocol as our prior retrospective review (data not
shown) indicated potential beneﬁt to MDS patients with any exposure to 5-
azacitidine. If a suitable donor was found, patients proceeded to allogeneic
HCT as soon as feasible, where the conditioning regimen was prescribed at
the discretion of the treating physician per institutional guidelines. Addi-
tional cycles of 5-azacitidine therapy were allowed while waiting for allo-
geneic HCT. The conditioning regimen was prescribed no longer than 8
weeks and no earlier than 4 weeks from the last dose of 5-azacitidine. Post-
transplantation disease staging studies were performed at 3, 6, and 12
months after allografting.
Patients without suitable donors continued 5-azacitidine per standard
treatment. These patients were followed until progression of MDS to AML or
death, for up to 1 year from time of ﬁrst dose of 5-azacitidine.
Assessments
A bone marrow biopsy was performed for assessment of disease
response either after the last cycle of 5-azacitidine before allogeneic HCT or
after the fourth cycle of 5-azacitidine, whichever occurred earlier. Disease
response was assessed per Cheson criteria [13] as modiﬁed by Silverman
et al. [12]. Complete blood counts were performed as needed to monitor
response and toxicity per standard practice. For monitoring, grade 3 or 4
toxicities (per Common Terminology Criteria for Adverse Events version 3.0)
occurring up to 30 days after the last dose of 5-azacitidine or at the start of
conditioning regimen considered related to 5-azacitidine were recorded.
Transplantation
Donors
Donors were related or unrelated and HLA-compatible for 7/8 or 8/8 at
HLA-A, -B, -C, and -DRB1 loci. All patients received granulocyte colonye-
stimulating factor emobilized unmanipulated peripheral blood hemato-
poietic cells.
Conditioning regimen
All patients who underwent transplantation received a modiﬁed de
Lima regimen of busulfan plus ﬂudarabine, which was adjusted to a speciﬁc
busulfan area under the curve (AUC) target [14,15]. Fludarabine was
administered at 40 mg/m2 daily intravenously for 4 days, with each infusion
followed immediately by intravenous busulfan. The dose of busulfan for
days 1 and 2 was 130 mg/m2. After the ﬁrst dose of busulfan, serial blood
samples were obtained for pharmacokinetic analysis. Accordingly, busulfan
dose for days 3 and 4 were adjusted to achieve a steady state targeted
busulfan AUC from 3500 to 7500 mM-min. One patient with a mismatched
unrelated donor graft at HLA-A locus received rabbit antithymocyte globulin
(ATG) at a total dose of 7.5 mg/kg over 3 days [16].
Supportive care for transplantation
All patients received lorazepam for seizure prophylaxis. Regimens for
graft-versus-host disease (GVHD) prophylaxis were tacrolimus and either
methotrexate, mycophenophate mofetil, or sirolimus. Methotrexate was
given at 15 mg/m2 intravenously on day þ1 and then 10 mg/m2 intrave-
nously on days þ3, þ6, and þ11. The dose of methotrexate was adjusted for
renal function. The dose of tacrolimuswas adjusted to achieve levels of 10 to
15 ng/mL during the ﬁrst month after allogeneic HCT and gradually
decreased in the absence of GVHD [17]. Mycophenolate mofetil was
administered at 30 mg/kg/day intravenously in 2 divided doses, beginning
on day 0 at least 2 hours after the end of the infusion of donor cells. The
tapering schedule began on day þ240 in the absence of GHVD per
institutional guidelines [17]. Sirolimus was administered at a loading dose of
12 mg on day -1, followed by maintenance to target sirolimus level of 8 to 14
ng/mL. For the tacrolimus/sirolimus combination, target tacrolimus level
was 3 to 7 ng/mL [18].Antimicrobial prophylaxis consisted of acyclovir, levoﬂoxacin, and
micafungin or voriconazole. Cytomegalovirus was monitored with weekly
real-time polymerase chain reaction of blood samples for the ﬁrst 100 days
after allogeneic HCT and pre-emptive therapy with ganciclovir, valganci-
clovir, or foscarnet was initiated per the institutional guidelines. Prophylaxis
for Pneumocystis jiroveci was with trimethoprim-sulfamethoxazole begin-
ning at day þ30. Granulocyte colonyestimulating factor was not routinely
administered after allogeneic HCT.
Statistical Analysis
The study was design to detect an improvement in 1-year RFS rate in
MDS patients who underwent transplantation from our institutional base-
line of 50% (unpublished data) to 80%. A total of 19 evaluable patients (who
were treated with 5-azacitidine and received allogeneic HCT) was estimated
to be needed to achieve 90% power to detect a 30% increase (1-sided test) in
1-year RFS rate at a 10% signiﬁcance level. If 13 or more of 19 evaluable
patients were relapse free, then the null hypothesis was rejected and the
study was deemed promising. The actual power and type I error are 93.2%
and 8.4%, respectively.
For descriptive statistics, categorical and continuous variables are
summarized as frequencies or percentages and as the median and range,
respectively. OS and RFS were estimated using Kaplan-Meier method [19].
The cumulative incidences of relapse, nonrelapsemortality, and acute GVHD
were estimated using the competing risk approach [20]. The 95% conﬁdence
interval (CI) for point estimates of cumulative incidences and survivals were
derived based on the log-log transformation [21].
Neutrophil engraftment after allogeneic HCT was deﬁned as the ﬁrst day
of absolute neutrophil count >0.5  109/L on 3 consecutive days. Platelet
engraftment was deﬁned as the ﬁrst day of platelet count >20  109/L for 7
days without transfusion support. Chimerism analyses were performed at
around day þ30, þ90, þ180, and þ365 using a polymerase chain reaction/
short tandem repeat method on unsorted bone marrow samples. Peripheral
blood CD3þ and CD33þ cell chimerism studies were also performed using
the subsets isolated by ﬂuorescence-activated cell sorting. Acute GVHD was
graded based on consensus conference criteria [22]. Chronic GVHD was
graded based on the National Institute of Health Consensus Development
Project [23]. Relapse and nonrelapse mortality were considered competing
risks of GVHD.
RESULTS
Patient, Disease, and Transplantation Characteristics
From May 2008 to August 2010, 25 patients with MDS
were enrolled in the study. Four patients did not proceed to
allogeneic HCT because of lack of insurance approval, sub-
optimal organ function, intracranial hemorrhage, and patient
refusal of allogeneic HCT. Except for 1 patient who did not
receive any 5-azacitidine, 3 non-HCT patients were followed
as described previously. Patient, disease, and transplantation
characteristics on 21 MDS patients who received allogeneic
HCT are summarized in Table 1.
The median age was 55 (range, 26 to 67) years and the
majority of allografted subjects were females (67%). Eleven
(58%) received hypomethylating agent(s) before enrollment,
with a median of 2 cycles (range, 1 to 5). Busulfan AUC target
levels were 3500 mM-min in 4 (19%), 5300 mM-min in 14
(67%), 6000 mM-min in 1 (5%), and 7500 mM-min in 2 (9%).
The majority received HLA-matched related or unrelated
donor grafts, except for 1 with a mismatched unrelated
donor (7/8). GVHD prophylaxis was predominantly tacroli-
mus plus methotrexate. ATG was given to 1 patient (Table 1).
Response and Safety of 5-Azacitidine
Twenty-one patients received a median of 3 (range, 0 to
6) cycles of 5-azacitidine on the study before allogeneic HCT.
The median total number of cycles (combining cycles before
and after enrollment) of 5-azacitidine before HCT was 4
(range, 1 to 6). Responses to 5-azacitidine included partial
response in 10 (48%), stable disease in 7 (33%), and pro-
gressive disease in 4 (19%). Three patients received AML-type
induction therapy before allogeneic HCT because of disease
progression during 5-azacitidine therapy. Grade 3 and 4
Table 1
Patient, Disease, and Transplantation Characteristics (N ¼ 21)
Characteristic Value
Age, median (range), yr 55 (26-27)
Gender
Male 7 (33%)
Female 14 (67%)
Disease at diagnosis
RCMD 4 (19%)
RAEB-1 4 (19%)
RAEB-2 11 (52%)
CMML-1 1 (5%)
AML 1 (5%)
IPSS at diagnosis (n ¼ 18)*
Intermediate-1 3 (17%)
Intermediate-2 10 (56%)
High 5 (27%)
IPSS-R at diagnosis (n ¼ 17)
Intermediate 3 (18%)
High 6 (35%)
Very high 8 (47%)
5-Azacitidine cycles, median (range) 3 (0-6)
Disease at allogeneic HCT
RCMD 9 (43%)
RAEB-1 6 (29%)
RAEB-2 3 (14%)
CMML 2 (10%)
AML 1 (5%)
Myeloblasts at allogeneic HCT
<5% 10 (48%)
5%-10% 7 (33%)
11%-20% 4 (19%)
>20% 0 (0%)
Donor
HLA-matched sibling 8 (38%)
HLA-matched unrelated (8/8) 12 (57%)
HLA-mismatched unrelated (7/8) 1 (5%)
GVHD prophylaxis
Tac/MTX 19 (90%)y
Tac/MMF 1 (5%)
Tac/Rapa 1 (5%)
RCMD indicates refractory cytopenias with multilineage dysplasia; RAEB,
refractory anemia with excess blasts; CMML, chronic myelomonocytic
leukemia; AML indicates acute myeloid leukemia; IPSS, International
Prognostic Scoring System; IPSS-R, Revised International Prognostic Scoring
System; HCT, hematopoietic cell transplantation; HLA, human leukocyte
antigen; GVHD, graft-versus-host disease; Tac, tacrolimus; MTX, metho-
trexate; MMF, mycophenolate mofetil; Rapa, rapamycin.
Data presented are n (%) unless otherwise indicated.
* IPSS information not available in 1 patient with RCMD.
y One patient received 50% dose reduction of MTX on day þ11.
Figure 1. Overall survival from the time of allogeneic hematopoietic cell
transplantation.
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Clostridium difﬁcile colitis (5%), nodular pneumonia (pre-
sumed fungal, 5%), perirectal abscess (5%), deep venous
thrombosis (5%), and cerebrovascular accident (5%).
Transplantation Outcomes
Neutrophil engraftment was achieved at a median of 15
(range, 12 to 22) days and platelet engraftment was achieved
at a median of 16 (range, 12 to 26) days. Two patients did not
engraft platelets. Early toxicities (within 30 days) after allo-
geneic HCT include hemorrhagic esophagitis (n ¼ 1), lower
extremity fasciitis after knee amputation (unrelated to HCT)
(n ¼ 1), posterior reversible encephalopathy syndrome (n ¼
1), and human herpes virus 6 encephalitis (n ¼ 1). The me-
dian donor chimerisms on unsorted bone marrow and pe-
ripheral blood CD3, and CD33 were as follows: at day þ30,
95% (range, 18% to 100%), 84% (range, 30% to 100%), and 100%
(range, 97% to 100%); at day þ100, 95% (range, 25% to 100%),
85% (range, 23% to 100%), and 100% (range, 97% to 100%),
respectively.In this cohort of patients, cumulative incidence of grade 2
to 4 acute GVHD was 100% with grade 3 to 4 acute GVHD of
14%. The organs involved for acute GVHD were the gastro-
intestinal tract in 90% (with 24% with upper gastrointestinal
tract involvement), skin in 67%, and liver in 17%. The cumu-
lative incidence of moderate to severe chronic GVHD was
38%. Day þ30 disease response was 95% CR with 1 patient
progressing to AML. Dayþ100 disease response was CR in 18
patients, 1 AML progression, 1 disease relapse, and 1 death.
The ﬁgures demonstrate OS (Figure 1), RFS (Figure 2), non-
relapse mortality (Figure 3), and cumulative incidence of
relapse (Figure 4), with a median follow-up of 30 months.
One-year RFS and OS were 52% (95% CI, 30% to 71%) and 62%
(95% CI, 38% to 79%), respectively. Two-year RFS and OS were
47% (95% CI, 25% to 66%) and 51% (95% CI, 28% to 70%),
respectively. Cumulative incidence of relapse was 14% (95%
CI, 3% to 33%) at 6 months and 24% (95% CI, 8% to 44%) at 1
year. Cumulative incidence of nonrelapse mortality was 5%
(95% CI, .3% to 20%) at 100 days, 24% (95% CI, 8% to 44%) at 1
year, and 29% (95% CI, 11% to 50%) at 2 years. Causes of death
include 4 disease relapses, 3 infectious complications, and 3
with GVHD and infections.
Outcomes of non-HCT Patients
The outcomes of the 3 non-HCT patients (except for 1
who did not receive further 5-azacitidine therapy) were the
following. One patient received achieved CR after 7 cycles of
5-azacitidine; however, this patient later died because of
progression to AML (no HCT was performed because of pa-
tient’s refusal). Another patient continued with 20 cycles of
5-azacitidine and then died because of progressive MDS. The
other patient, who received 1 cycle of 5-azacitidine, died
because of complications from pneumonia.
DISCUSSION
In this pilot study, with 21MDS patients with adverse risk
factors who were prospectively treated with 5-azacitidine
before allogeneic HCT, we found that pre-HCT hypo-
methylating agent therapy with 5-azacitidine is feasible and
provides a reasonable disease control before HCT with
busulfan/ﬂudarabine regimen. Additionally, as our institu-
tional reference, we evaluated 63 patients from July 2004 to
December 2010 who did not receive 5-azacitidine before
Figure 2. Relapse-free survival from the time of allogeneic hematopoietic cell
transplantation.
Figure 4. Cumulative incidence of relapse.
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and 36.4% at 2 years, respectively. Although no formal sta-
tistical analyses were performed, our study of pre-HCT
hypomethylating agent resulted in favorable 1-year RFS
and OS of 52% (95% CI, 30% to 71%) and 62% (95% CI, 38% to
79%), respectively. The median number of cycles of 5-
azacitidine given was 3 (range, 0 to 6) and this strategy
allowed ample time for a donor search before allogeneic HCT.
Although there were 11 patients (58%) who received hypo-
methylating agents before enrollment, patients were
enrolled to the study early in treatment and the authors do
not believe that there was any signiﬁcant impact on the
study outcomes, even when accounting for the pre-
enrollment treatment. Therapy with 5-azacitidine did not
impose excess toxicity before allogeneic HCT.We did observe
higher cumulative incidence of acute grade 2 to 4 GVHD, but
this may be confounded by predominantly unrelated donor
sources and a small sample size. Acute GVHD occurred pre-
dominantly in gastrointestinal tract with a quarter of pa-
tients having mostly upper gastrointestinal symptoms.
Whether pre-HCT 5-azacitidine contributed to the develop-
ment of acute GVHD will need to be evaluated in a larger
cohort of patients. The limitations of our pilot study includeFigure 3. Nonrelapse mortality from the time of allogeneic hematopoietic cell
transplantation.single-arm study design and a small sample size, as the
intent was to evaluate the feasibility of this pre-HCT
approach.
As corroborated by our previous retrospective study [9],
several groups have retrospectively evaluated the role and
feasibility of hypomethylating agent (either 5-azacitidine or
decitabine) therapy before allogeneic HCT [6,7,9, 24-26].
Single-agent therapy with hypomethylating agent would be
of value in stabilizing the disease or reverting it to an earlier
stage, as was seen in our study, and allowing time for pa-
tients to reach the more curative allogeneic HCT. Some have
suggested that achievement of CR with a hypomethylating
agent might improve outcomes after allogeneic HCT [6];
however, although none of our study patients achieved CR,
many proceeded with HCT, and the prospective validation of
this observation is needed. In a large retrospectively study by
the French Bone Marrow Transplant registry, Damaj et al.
evaluated 48 patients treatedwith 5-azacitidine alone and 17
patients with 5-azacitidine followed by induction chemo-
therapy before allogeneic HCT compared with 163 MDS pa-
tients who received induction therapy alone [7]. Patients
treated with 5-azacitidine alone had comparable OS and
event-free survival compared with the induction therapy
group. Gerds et al. evaluated the outcomes of 68 patients
who underwent allogeneic HCT for MDS or AML transformed
fromMDS [26]. Thirty-ﬁve received 5-azacitidine before HCT
and 33 received induction chemotherapy. One-year OS was
57% with azacitidine and 36% with induction therapy. After
adjustment for cytogenetic risk, International Prognostic
Scoring System, and the donor status, the rates of post-HCT
relapse for 2 cohorts were similar [26].
Data on whether “debulking” before allogeneic HCT to
suppress bone marrow blasts count to less than 10% or
down-staging of MDS would improve post-HCT disease
relapse are inconclusive [9,10]. Lubbert et al. argue that
delaying HCT to achieve major cytoreduction may result in
complications that prohibit HCT or development of drug
resistance with concomitant disease progression [27]. Addi-
tionally, there is inherent physician bias to provide such
therapy to high-riskMDS patients, and prospective studies to
evaluate the role of debulking are needed before deﬁnitive
conclusions can be made.
Disease that fails 5-azacitidine has a very poor prognosis.
Prebet et al. investigated the outcomes in this group [28]. Out
of 270 patients with available information of subsequent
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allogeneic HCT with a median OS of 19.5 months. Twenty-
eight patients received immediate allogeneic HCT and 9
went to HCT after 1 or more cycles of salvage therapy.
Fourteen had progressive disease and underwent allogeneic
HCT with a median OS of 14 months, whereas 14 with stable
disease had not reachedmedian survival after allogeneic HCT
at the time of publication (P ¼ .08), suggesting the beneﬁt of
allogeneic HCT, even without a favorable response to 5-
azacitidine treatment [28].
Relapse after allogeneic HCT remains the major cause of
treatment failure. A study by de Lima et al. evaluated the role
of low-dose azacitidine (32 mg/m2 given for 5 days at least
4 cycles) maintenance early after allogeneic HCT [29].
Approximately 60% of patients were able to receive at least 1
cycle of therapy and there was a suggestion that the main-
tenance therapy may prolong event-free and OS. The optimal
allogeneic HCT strategy for high-risk MDS is not fully deﬁned
and current treatment options continue to evolve. Both pre-
HCT disease-speciﬁc or disease-modifying therapy, incorpo-
rating a hypomethylating agent, and post-HCT maintenance
or pre-emptive therapy to reduce disease relapse after allo-
geneic HCT could be incorporated in the ideal platform for
allogeneic HCT in patients with MDS. Further research with
prospective studies is needed to optimize allogeneic HCT
strategy to produce long-term disease control.
CONCLUSIONS
Pretransplantation 5-azacitidine therapy was well toler-
ated and provided reasonable disease control. This regimen
served adequately in our small patient cohort as a bridge to
allogeneic HCT and did not impose any additional toxicity
after allogeneic HCT with a promising 1-year RFS. Future
clinical trials are needed to determine the optimal schedule
and strategy to improve postallogeneic HCT relapse risk and
survival with incorporation of pretransplantation 5-
azacitidine therapy.
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